# Antimicrobial prophylaxis in hematopoietic stem cell transplantation (HSCT) patients: guidelines and evidence

Philipp Wohlfarth

Stem Cell Transplantation Unit

Medical University of Vienna

# Hematopoietic stem cell transplantation (HSCT)




Passweg, BMT 2017

# Hematopoietic stem cell transplantation (HSCT)

## Allogeneic HSCT




## Autologous HSCT




Passweg, BMT 2018

# Hematopoietic stem cell transplantation (HSCT)




- **Autologous HSCT**

  Infusion of the patient‘s own hematopoietic stem cells after prior harvest and storage

- **Allogeneic HSCT**

  Infusion of hematopoietic stem cells from a non-self related or unrelated donor according to genetic matching (HLA compatibility)

# Stem Cell Source

**Bone marrow**

**Peripheral blood**
(Leukapheresis after G-CSF mobilization)



**Cord blood**

# Hematopoietic stem cell transplantation (HSCT)

- **Autologous HSCT**

  → **Aim: dose-escalation of cytotoxic therapy** with *autologous* rescue of the hematopoietic system

- **Allogeneic HSCT**

  → **Aim 1: dose-escalation of cytotoxic therapy** with *allogeneic* rescue of the hematopoietic system

  → **Aim 2:** activity **(immune effect)** of the transferred immune system against residual malignant cells

**(graft-versus-host disease) GVHD** ⟷ **GVL (graft-versus-leukemia effect)**

# Risk for infection after HSCT

**Allogeneic HSCT**  **Autologous HSCT**

- Type of conditioning therapy
- *In vivo* T-cell depletion (anti-thymocyte globulin [ATG])
- More extensive mucosal injury during conditioning
- Immunosuppressive therapy (CNIs, MMF, MTX, ***corticosteroids [!]***)
- Immunodisparity (increased risk of infection with HLA mismatches)
- Graft-versus-host disease (GVHD)

# Risk for infection after HSCT

- Age
- Comorbidities
- Diagnosis *(previous therapies [!])*
- Prior infections of the donor and/or the recipient
- Pre-transplant specific immunity to *cytomegalovirus* (CMV), *herpes simplex virus* (HSV), *varicella-zoster virus* (VZV), and/or *Epstein-Barr virus* (EBV)

**Patient-related risk factors**

# General measures to reduce the risk of infection

- Environmental measures

  Neutropenic diet, no plants, wearing of masks, isolated patient rooms, laminar air flow etc.

- Donor selection

  HLA matching, Donor/recipient CMV serostatus, Donor/recipient hepatitis B virus serostatus, pre-HSCT testing

- Conditioning regimen and dose of hematopoietic stem cells

  Avoidance of T-cell depletion, shorter duration of aplasia

- Avoidance of excessive immunosuppression and myelosupression

  No glucocorticoids for GVHD prophylaxis, lowest possible dose and rapid taper of glucocorticoids for GVHD treatment, avoid myelosuppressive drugs (e.g. MMF, TMP-SMX etc.)

- **Antimicrobial prophylaxis or pre-emptive therapy**

# Infections after *allogeneic* HSCT




Tomblyn, BBMT 2009

# Infections after *autologous* HSCT




UpToDate ©

# Antimicrobial prophylaxis in HSCT - guidelines

European Conference on Infections in Leukemia (ECIL)

Infectious Diseases Society of America (IDSA)

National Guidelines

# Antibacterial prophylaxis in HSCT




- Started from the beginning of neutropenia (absolute neutrophil count [ANC] <500/µl) and given until hematopoietic recovery
- **Fluorchinolone (FQ) prophylaxis** most widely studied regimen (ciprofloxacin or levofloxacin)

# Antibacterial prophylaxis in HSCT – meta-analyses

| | Cochrane, 2012 | ECIL, 2018 |
|---|---|---|
| Studies | 109 RCTs (1973-2010) | 2 RCTs, 12 observational studies (2006-2014) |
| Patients | Afebrile neutropenic patients | |
| Fever during neutropenia | | |
| Blood stream infections | | |
| **Mortality** | | |

Gafter-Gvili, Cochrane Database Syst Rev. 2012
Mikulska, J Infect. 2018

# Antibacterial prophylaxis in HSCT – meta-analyses

| | Cochrane, 2012 | ECIL, 2018 |
|---|---|---|
| Studies | 109 RCTs (1973-2010) | 2 RCTs, 12 observational studies (2006-2014) |
| Patients | Afebrile neutropenic patients | |
| Fever during neutropenia | ↓ (RR 0.80; 95%CI: 0.74-0.87) | ↓ (OR 0.32; 95%CI: 0.20-0.50) |
| Blood stream infections | | |
| **Mortality** | | |

Gafter-Gvili, Cochrane Database Syst Rev. 2012
Mikulska, J Infect. 2018

# Antibacterial prophylaxis in HSCT – meta-analyses

| | Cochrane, 2012 | ECIL, 2018 |
|---|---|---|
| Studies | 109 RCTs (1973-2010) | 2 RCTs, 12 observational studies (2006-2014) |
| Patients | Afebrile neutropenic patients | |
| Fever during neutropenia | ↓ (RR 0.80; 95%CI: 0.74-0.87) | ↓ (OR 0.32; 95%CI: 0.20-0.50) |
| Blood stream infections | ↓ (RR 0.51; 95%CI: 0.42-0.62) | ↓ (OR 0.57; 95%CI: 0.43-0.74) |
| **Mortality** | | |

Gafter-Gvili, Cochrane Database Syst Rev. 2012
Mikulska, J Infect. 2018

# Antibacterial prophylaxis in HSCT – meta-analyses

| | Cochrane, 2012 | ECIL, 2018 |
|---|---|---|
| Studies | 109 RCTs (1973-2010) | 2 RCTs, 12 observational studies (2006-2014) |
| Patients | Afebrile neutropenic patients | |
| Fever during neutropenia | ↓ (RR 0.80; 95%CI: 0.74-0.87) | ↓ (OR 0.32; 95%CI: 0.20-0.50) |
| Blood stream infections | ↓ (RR 0.51; 95%CI: 0.42-0.62) | ↓ (OR 0.57; 95%CI: 0.43-0.74) |
| **Mortality** | ↓ (RR 0.66; 95%CI: 0.55-0.79) | |

Gafter-Gvili, Cochrane Database Syst Rev. 2012
Mikulska, J Infect. 2018

# Antibacterial prophylaxis in HSCT – meta-analyses

| | Cochrane, 2012 | ECIL, 2018 |
|---|---|---|
| Studies | 109 RCTs (1973-2010) | 2 RCTs, 12 observational studies (2006-2014) |
| Patients | Afebrile neutropenic patients | |
| Fever during neutropenia | ↓ (RR 0.80; 95%CI: 0.74-0.87) | ↓ (OR 0.32; 95%CI: 0.20-0.50) |
| Blood stream infections | ↓ (RR 0.51; 95%CI: 0.42-0.62) | ↓ (OR 0.57; 95%CI: 0.43-0.74) |
| **Mortality** | ↓ (RR 0.66; 95%CI: 0.55-0.79) | = (OR 1.01; 95%CI: 0.73-1.41) |

Gafter-Gvili, Cochrane Database Syst Rev. 2012
Mikulska, J Infect. 2018

# Antibacterial prophylaxis in HSCT – concerns

- Several studies report an increase in **colonisation** or **blood stream infections** with **FQ-resistant *and/or* MDR bacteria**

  → 32% risk for blood stream infections in HSCT patients colonized with ESBL+ enterobacteriaceae *(Satlin, Clin Infect Dis 2018)*

  → 74% vs. 8% of FQ-resistant and 42% vs. 10% of ESBL+ bacteria in surveillance stool samples of HSCT recipients *(Verlinden, Eur J Hematol 2014)*

- Alters the composition of the **gut microbiome**, therefore putative associations with

  → risk of relapse *(Peled, JCO 2017)*

  → non-relapse mortality and GVHD risk *(Taur, Blood 2014; Shono, Science Transl Med 2016)*

  → response to immunotherapy *(Routy, Science 2018; Matson, Science 2018)*

# Antibacterial prophylaxis in HSCT - guidelines

- **Use of FQ prophylaxis during neutropenia is heavily debated**, decreasing use in Europe
- Accumulating data on the effect of the gut microbiome on major end-points, such as incidence of disease relapse, efficacy of immunotherapy etc., might shift this balance further
- Current recommendations:

**Neutral**
**– weigh risks against benefits**

ECIL Guidelines 2018

**Recommended**
**– in HSCT recipients undergoing myeloablative conditioning**

IDSA Guidelines 2018

# Antibacterial prophylaxis in HSCT - guidelines

- **Patients with severe chronic GVHD + immunosuppressive treatment (steroids!)** are at high risk for infections with **encapsulated bacteria** *(e.g. Streptococcus pneumonia)* due to functional asplenia
- → Recommended use of **long-term prophylactic antibiotics** in these patients (e.g. TMP/SMX, levofloxacin, cefalexine, penicillin V)
  (Tomblyn, BBMT 2009)





Howel-Jolly bodies in a patient with chronic GVHD as a sign of functional asplenia

# Antifungal prophylaxis in HSCT




| | | Yeasts | | | | | | Molds | |
|---|---|---|---|---|---|---|---|---|---|
| | | Candida albicans | Candida glabrata | Candida parapsilosis | Candida tropicalis | Candida krusei | Candida lusitaniae | Aspergillus fumigatus | Mucorales |
| Yeast-active | Fluconazole | ++ | +/- | ++ | ++ | - | ++ | - | - |
| | Echinocandins | ++ | + | ++ | ++ | ++ | ++ | +/- | - |
| Mold-active | Amphotericin B | ++ | ++ | ++ | ++ | ++ | - | ++ | ++ |
| | Itraconazole | ++ | +/- | ++ | ++ | +/- | ++ | ++ | - |
| | Voriconazole | ++ | ++ | ++ | ++ | ++ | ++ | ++ | - |
| | Posaconazole | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| | Isavuconazole | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |

Souza, Front Microbiol 2017

# Antifungal prophylaxis in HSCT – data

- 16-18% incidence of pre-engraftment invasive candidiasis in patients undergoing myeloablative allogeneic HSCT prior to fluconazole prohylaxis (Goodman, NEJM 1992; Slavin, J Infect Dis 1995)

| | Robenshtok, JCO 2007 | | | |
|---|---|---|---|---|
| Studies | 64 RCTs (1966-2007) | | | |
| Intervention | **Fluconazole/Itraconazole/Posaconazole** | | | |
| Comparator | **No systemic antifungal** | | | |
| Patients | All patients | Allogeneic HSCT | | |
| Documented IFI | ↓ (RR 0.50; 95%CI: 0.41-0.61) | ↓ (RR 0.33; 95%CI: 0.18-0.63) | | |
| IFI-related mortality | ↓ (RR 0.55; 95%CI: 0.41-0.57) | ↓ (RR 0.52; 95%CI: 0.27-0.99) | | |
| **All-cause Mortality** | ↓ (RR 0.84; 95%CI: 0.74-0.95) | ↓ (RR 0.62; 95%CI: 0.45-0.85) | | |
| **Drug discontinuation** | | | | |

* for itraconazole vs. fluconazole; confirmed for other triazoles in Ethier, Br J Cancer 2012

Robenshtok, JCO 2007
Wingard, Blood 2010

# Antifungal prophylaxis in HSCT – data

- 16-18% incidence of pre-engraftment invasive candidiasis in patients undergoing myeloablative allogeneic HSCT prior to fluconazole prohylaxis (Goodman, NEJM 1992; Slavin, J Infect Dis 1995)

| | Robenshtok, JCO 2007 | | | |
|---|---|---|---|---|
| Studies | 64 RCTs (1966-2007) | | | |
| Intervention | **Fluconazole/Itraconazole/Posaconazole** | | **Fluconazole** | |
| Comparator | **No systemic antifungal** | | **Anti-mold agent** | |
| Patients | All patients | Allogeneic HSCT | All patients | |
| Documented IFI | ↓ (RR 0.50; 95%CI: 0.41-0.61) | ↓ (RR 0.33; 95%CI: 0.18-0.63) | = (RR 1.40; 95%CI: 0.91-2.14) | |
| IFI-related mortality | ↓ (RR 0.55; 95%CI: 0.41-0.57) | ↓ (RR 0.52; 95%CI: 0.27-0.99) | ↑ (RR 1.58; 95%CI: 1.00-2.50) | |
| **All-cause Mortality** | ↓ (RR 0.84; 95%CI: 0.74-0.95) | ↓ (RR 0.62; 95%CI: 0.45-0.85) | = (RR 1.14; 95%CI: 0.95-1.37) | |
| **Drug discontinuation** | | | ↓ (RR 0.40; 95%CI: 0.30-0.52)* | |

* for itraconazole vs. fluconazole; confirmed for other triazoles in Ethier, Br J Cancer 2012

Robenshtok, JCO 2007
Wingard, Blood 2010

# Antifungal prophylaxis in HSCT – data

- 16-18% incidence of pre-engraftment invasive candidiasis in patients undergoing myeloablative allogeneic HSCT prior to fluconazole prohylaxis (Goodman, NEJM 1992; Slavin, J Infect Dis 1995)

| | Robenshtok, JCO 2007 | | | Wingard, Blood 2010 |
|---|---|---|---|---|
| Studies | 64 RCTs (1966-2007) | | | RCT (n=600) |
| Intervention | **Fluconazole/Itraconazole/Posaconazole** | | **Fluconazole** | **Voriconazole** |
| Comparator | **No systemic antifungal** | | **Anti-mold agent** | **Fluconazole** |
| Patients | All patients | Allogeneic HSCT | All patients | Allogeneic HSCT |
| Documented IFI | ↓ (RR 0.50; 95%CI: 0.41-0.61) | ↓ (RR 0.33; 95%CI: 0.18-0.63) | = (RR 1.40; 95%CI: 0.91-2.14) | =/↓ (7.3% vs. 11.2%; p=0.12) |
| IFI-related mortality | ↓ (RR 0.55; 95%CI: 0.41-0.57) | ↓ (RR 0.52; 95%CI: 0.27-0.99) | ↑ (RR 1.58; 95%CI: 1.00-2.50) | |
| **All-cause Mortality** | ↓ (RR 0.84; 95%CI: 0.74-0.95) | ↓ (RR 0.62; 95%CI: 0.45-0.85) | = (RR 1.14; 95%CI: 0.95-1.37) | = (81% vs. 72%; p=0.32) |
| **Drug discontinuation** | | | ↓ (RR 0.40; 95%CI: 0.30-0.52)* | = (44% vs. 40%; p=n.s.) |

* for itraconazole vs. fluconazole; confirmed for other triazoles in Ethier, Br J Cancer 2012

Robenshtok, JCO 2007
Wingard, Blood 2010

# Antifungal prophylaxis in HSCT – shift in IFI patterns







Kontoyiannis, Clin Infect Dis 2010

# Antifungal prophylaxis in HSCT – GVHD *and/or* steroids

- Allogeneic HSCT patients with **acute GVHD grade >2/chronic GVHD + systemic prednisone treatment** are at considerable risk for IFIs, espcially invasive aspergillosis (Wingard, Blood 2010; Ullman, NEJM 2007)




The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 JANUARY 25, 2007 VOL. 356 NO. 4

Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

| Pathogen or Pathogen Group | Posaconazole Group (N=291) | Fluconazole Group (N=288) | Odds Ratio (95% CI) | P Value |
|---|---|---|---|---|
| | *no. (%)* | | | |
| **Exposure period†** | | | | |
| All proven and probable invasive fungal infections* | 7 (2.4) | 22 (7.6) | 0.30 (0.12–0.71) | 0.004 |
| All invasive aspergillosis | 3 (1.0) | 17 (5.9) | 0.17 (0.05–0.57) | 0.001 |

Ullman, NEJM 2007

# Antifungal prophylaxis in HSCT - guidelines

- Pre-engratment antifungal prophylaxis is recommended in patients undergoing **myeloablative allogeneic HSCT** and **depends on the local rate of invasive mold infections:**

  → ≤5-6% - fluconazole

  → >5-6% - voriconazole or posaconazole (ECIL & IDSA)

- Pre-engraftment antifungal prophylaxis with fluconazole **can be considered (ECIL)** in **autologous HSCT** recipients

- Post-engraftment anti-mold prophylaxis (voriconazole or posaconazole) **should be given to allogeneic HSCT patients with GVHD and/or receiving prednisone ≥ 1 mg/kg** (ECIL & IDSA)

# Antifungal prophylaxis in HSCT - TDM

- **Therapeutic drug monitioring (TDM) is recommended for itraconazole, voriconazole and posaconazole (ECIL)**
- Posaconazole tablets or iv. formulation are preferred over oral solution (ECIL)
- Do not give azoles during conditioning phase!
- Be aware of drug interactions!

| Triazole | Recommended plasma range | Strength of recommendation | Timing of first trough sample |
|---|---|---|---|
| Voriconazole | Prophylaxis and treatment:<br>Acceptable : 1-6 mg/L;<br>Optimal: 2-5 mg/L | AII (efficacy)<br>AII (toxicity) | After 2-5 days; (repeat sampling recommended) |
| Posaconazole | Prophylaxis: >0.7 mg/L<br>Treatment: >1.0 mg/L | BII (efficacy)<br>AII (efficacy) | Tablet/IV: after 3 days<br>Suspension: 5-7 days |
| Itraconazole | Prophylaxis: 0.5-4 mg/L<br>Treatment: 1-4 mg/L | AII (efficacy)<br>BII (toxicity) | 7-15 days |

ECIL summary slides 2015

# Antifungal prophylaxis in HSCT - resistance

*J Antimicrob Chemother* 2015; **70**: 1522–1526
doi:10.1093/jac/dku566 Advance Access publication 27 January 2015

Journal of Antimicrobial Chemotherapy

**Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany**

J. Steinmann[1]*†, A. Hamprecht[2]†, M. J. G. T. Vehreschild[3,4], O. A. Cornely[3–5], D. Buchheidt[6], B. Spiess[6], M. Koldehoff[7], J. Buer[1], J. F. Meis[8,9] and P.-M. Rath[1]

8/27 cases (30%)

1274 THE NEW ENGLAND JOURNAL OF MEDICINE Oct. 31, 1991

**INCREASE IN *CANDIDA KRUSEI* INFECTION AMONG PATIENTS WITH BONE MARROW TRANSPLANTATION AND NEUTROPENIA TREATED PROPHYLACTICALLY WITH FLUCONAZOLE**

JOHN R. WINGARD, M.D., WILLIAM G. MERZ, PH.D., MICHAEL G. RINALDI, PH.D., THOMAS R. JOHNSON, M.D., JUDITH E. KARP, M.D., AND REIN SARAL, M.D.

1% vs. 8% infection rate

**Surveillance for Azole-Resistant *Aspergillus fumigatus* in a Centralized Diagnostic Mycology Service, London, United Kingdom, 1998–2017**

frontiers in Microbiology
1998–2017. Front. Microbiol. 9:2234.
doi: 10.3389/fmicb.2018.02234

*Alireza Abdolrasouli[1,2]*, Michael A. Petrou[1], Hyun Park[3], Johanna L. Rhodes[4], Timothy M. Rawson[5,6], Luke S. P. Moore[5,6,7], Hugo Donaldson[6], Alison H. Holmes[5,6], Matthew C. Fisher[4] and Darius Armstrong-James[2]*

0.43% (1998-2011)
↑
2.2% (2015-2017)

MAJOR ARTICLE

**Increasing Echinocandin Resistance in *Candida glabrata*: Clinical Failure Correlates With Presence of *FKS* Mutations and Elevated Minimum Inhibitory Concentrations**

Barbara D. Alexander,[1] Melissa D. Johnson,[1] Christopher D. Pfeiffer,[1,a] Cristina Jiménez-Ortigosa,[3] Jelena Catania,[1] Rachel Booker,[2] Mariana Castanheira,[4] Shawn A. Messer,[4] David S. Perlin,[3] and Michael A. Pfaller[4]

[1]Duke University, Durham, and [2]Campbell University College of Pharmacy and Health Sciences, Buies Creek, North Carolina; [3]Public Health Research Institute, New Jersey Medical School–UMDNJ, Newark; and [4]JMI Laboratories, North Liberty, Iowa

5% ↑ 12%
(2001-2010)

# Anti-*Pneumocystis jirovecii* pneumonia (PJP) prophylaxis in HSCT





- Incidence 5-37% in allogeneic HSCT recipients without prophylaxis
- Impared lymphoid reconstitution as the most important risk factor
- **Mortality as high as 60%**

Williams, BMT 2016

# Anti-PJP prophylaxis in HSCT - guidelines

- Prophylaxis against *Pneumocystis jirovecii* pneumonia (PJP) should be given to **all allogeneic HSCT recipients for at leasts 6 months *or* until the cessation of immunosuppressive therapy** (whatever occurs later) to prevent pneumonia (ECIL)

- Anti-PCP prophylaxis should be given to all patients receiving **prolonged therapy with systemic steroids** (e.g. prednisone >20 mg/day for 4 weeks) (ECIL & IDSA)

- **Trimethoprim/sulfamethoxazole (TMP/SMX)** is the drug of choice (also effective against *Toxoplasma gondii*); pentamidine, atovaquone and dapsone can be considered second-line choices (ECIL)

- **No recommendations** regarding anti-PJP prophylaxis for **autologous HSCT patients**

# Anti-viral prohylaxis in HSCT




- **<u>Herpes simplex virus (HSV)</u>**

  → prophylaxis with acyclovir/valacyclovir **in all seropositive HSCT patients** from the start of conditioning until engraftment or mucositis is resolved (ECIL & IDSA)

- **<u>Varicella zoster virus (VZV)</u>**

  → prophylaxis with acyclovir/valacyclovir **in all seropositive HSCT patients** for at least 1 year *<u>or</u>* 6 months from the cessation of all immunosupressive therapy, whatever occurs later (ECIL & IDSA)

# Anti-viral prohylaxis in HSCT

JAMA | Original Investigation

## Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation
### A Randomized Clinical Trial

Adriana Bastidas, MD; Javier de la Serna, MD; Mohamed El Idrissi, MSc; Lidia Oostvogels, MD; Philippe Quittet, MD; Javier López-Jiménez, MD, PhD; Filiz Vural, MD; David Pohlreich, MD; Tsila Zuckerman, MD; Nicolas C. Issa, MD; Gianluca Gaidano, MD, PhD; Je-Jung Lee, MD; Sunil Abhyankar, MD; Carlos Solano, MD, PhD; Jaime Perez de Oteyza, MD, PhD; Michael J. Satlin, MD; Stefan Schwartz, MD; Magda Campins, MD, PhD; Alberto Rocci, MD, PhD; Carlos Vallejo Llamas, MD, PhD; Dong-Gun Lee, MD, PhD; Sen Mui Tan, MD; Anna M. Johnston, MBBS; Andrew Grigg, MBBS, FRACP, MD; Michael J. Boeckh, MD, PhD; Laura Campora, MD; Marta Lopez-Fauqued, PhD; Thomas C. Heineman, MD, PhD; Edward A. Stadtmauer, MD; Keith M. Sullivan, MD; for the ZOE-HSCT Study Group Collaborators







Bastidas, JAMA 2019

# Anti-viral prohylaxis in HSCT - CMV

- **<u>Cytomegalovirus (CMV)</u>**

  → used to be a major factor for morbidity and mortality after **allogeneic HSCT** ***(pneumonitis, colitis/enteritis);*** no/very little relevance in **autologous HSCT recipients**

  → acyclovir and valacyclovir are largely ineffective against CMV

  → **ganciclovir and valganciclovir** are the most effective agents (alongside **foscarnet** and **cidofovir**)



Acyclovir



Ganciclovir



Valacyclovir



Valganciclovir

# Anti-viral prohylaxis in allogeneic HSCT - CMV

→ Prophylactic use of ganciclovir and valganciclovir are limited by **hematotoxicity (~30%)**

→ **Pre-emptive therapy** (monitoring of viral reactivation with DNA PCR/antigen detection and early therapy) are equally effective in reducing CMV disease and **are the recommended strategy (ECIL**)

***Figure 3.*** Cumulative incidence of CMV DNA positivity.




***Figure 2.*** Cumulative incidence of the primary end point.




Boeckh, Ann Int Med 2015

# Anti-viral prohylaxis in allogeneic HSCT - CMV

**Regular Article**

IMMUNOBIOLOGY

**Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis**

Pierre Teira,[1,*] Minoo Battiwalla,[2,*] Muthalagu Ramanathan,[3,*] A. John Barrett,[2,*] Kwang Woo Ahn,[4,5] Min Chen,[4] Jaime S. Green,[6] Ayman Saad,[7] Joseph H. Antin,[8] Bipin N. Savani,[9] Hillard M. Lazarus,[10] Matthew Seftel,[11] Wael Saber,[4] David Marks,[12] Mahmoud Aljurf,[13] Maxim Norkin,[14] John R. Wingard,[14] Caroline A. Lindemans,[15] Michael Boeckh,[16] Marcie L. Riches,[17] and Jeffery J. Auletta[18]




**Figure 1. Cumulative incidence curves for CMV reactivation according to D/R serology.**




Teira, Blood 2016

# Anti-viral prohylaxis in allogeneic HSCT - letermovir

- Phase III, double-blinded RCT
- n=565
- Allogeneic HSCT recipients seropositive for CMV (R+), irrespective of donor status (D+/-)


ORIGINAL ARTICLE

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

F.M. Marty, P. Ljungman, R.F. Chemaly, J. Maertens, S.S. Dadwal, R.F. Duarte, S. Haider, A.J. Ullmann, Y. Katayama, J. Brown, K.M. Mullane, M. Boeckh, E.A. Blumberg, H. Einsele, D.R. Snydman, Y. Kanda, M.J. DiNubile, V.L. Teal, H. Wan, Y. Murata, N.A. Kartsonis, R.Y. Leavitt, and C. Badshah

- **Intervention:**

**Letermovir 480 mg p.o./i.v. (240 mg in patients receiving cyclosporine** → drug interaction!) started before day +28 after HSCT and continued until week +14 (~day +100)

- **Continuation of VZV/HSV prophylaxis**; start pre-emptive therapy with (val-)ganciclovir at ~150-350 copies/mL CMV

Marty, NEJM 2017

# Anti-viral prohylaxis in allogeneic HSCT - letermovir




Marty, NEJM 2017

# Anti-viral prohylaxis in allogeneic HSCT - letermovir




- **Lower mortality in the letermovir group at week 24** (10.2% [95% CI, 6.8 to 13.6] vs. 15.9% [95% CI, 10.2 to 21.6], P=0.03)

Marty, NEJM 2017

# Anti-viral prohylaxis in allogeneic HSCT - letermovir

| Side effect | Letermovir | Placebo |
|---|---|---|
| Vomiting | 19% | 14% |
| Edema | 15% | 9% |
| Atrial fibrillation/flutter | 5% | 1% |
| Myalgia | 5% | 2% |

- No hematotoxicity
- 2% discontinuation rate due to adverse events
- 1 patient with breakthrough resistant CMV infection (UL56 V235M mutation)

Marty, NEJM 2017

# Anti-viral prohylaxis in allogeneic HSCT - letermovir

- **Provisional AI recommendation for CMV prophylaxis in allogeneic HSCT recipients in the ECIL-7 guidelines** (Ljungman, Lancet Hematology 2019)

  → Mistake in your hand-outs, please correct!

- Duration of prophylaxis beyond day +100?

- Not evaluated for pre-emptive treatment or treatment of CMV disease

# Anti-viral prohylaxis in HSCT

- **Epstein-Barr Virus (EBV)**

→ **screening and monitoring for EBV replication** in peripheral blood in allogeneic HSCT recipients at risk for post-transplant lymphoproliferative disease (PTLD) (ECIL & IDSA)

→ **reduction of immunosuppression or pre-emptive treatment** with rituximab or cytotoxic lymphocytes (CTLs) in allogeneic HSCT patients with uncontrolled reactivation (ECIL)

→ no need to monitor EBV in autlogous HSCT patients

# Anti-viral prohylaxis in HSCT

- **Hepatitis B virus (HBV)**

  → antiviral prophylaxis with entecavir, tenofovir or lamivudine in HBV infected HSCT recipients at high risk of an HBV flare (HbsAg-positive or DNA positive)

  → risk-adapted approach in patients with prior exposure to HBV (HBcAb-positive, HBsAg-negative, HBsAb-positive/negative)

- **Vaccination**

  → (repeat) vaccinations for influenza, hepatitis, and varizella zoster (recombinant) following HSCT; also pneumococci, meningococci, polio